|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12345678910111213...3940» |
- | Trial primary completion date: Measuring Time Windows in Patients With Schizophrenia and Healthy Controls (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=228, Recruiting, Sponsor: University Hospital, Strasbourg, France
Trial primary completion date: Dec 2016 --> Dec 2017
- | Trial primary completion date: Social Cognition Training in Schizophrenia (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=25, Recruiting, Sponsor: Oslo University Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- | NN1213 / Novo Nordisk
Phase classification, HEOR: Quality of Life and Mental Health in Children and Adolescents (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=2342, Completed, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Jun 2017 --> Jan 2018 Phase classification: P2/3 --> P=N/A
- | Phase classification: Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=33, Completed, Sponsor: Norwegian University of Science and Technology
Phase classification: P2/3 --> P=N/A Phase classification: P2 --> P=N/A
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Mar 29, 2017
P4, N=59, Completed, Sponsor: New York State Psychiatric Institute
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed
- | Trial completion: Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=546, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | olanzapine / Generic mfg., ziprasidone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Antipsychotics and Gene Expression in Soft Tissues (clinicaltrials.gov) - Mar 23, 2017
P4, N=16, Completed, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Suspended --> Completed | N=42 --> 16 | Trial primary completion date: Dec 2017 --> Jan 2017
- | JNJ-39393406 / J&J
Trial completion: Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) - Mar 23, 2017
P2, N=62, Completed, Sponsor: K.N. Roy Chengappa
Suspended --> Completed | N=42 --> 16 | Trial primary completion date: Dec 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Enrollment closed: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Mar 22, 2017
P4, N=200, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change: Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial (clinicaltrials.gov) - Mar 20, 2017
P=N/A, N=25, Completed, Sponsor: King's College London
Recruiting --> Active, not recruiting Recruiting --> Completed | N=34 --> 25
- | Trial completion: BUCCODOR: Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in C (clinicaltrials.gov) - Mar 17, 2017
P=N/A, N=110, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Recruiting --> Completed | N=34 --> 25 Recruiting --> Completed
- | Trial completion: Probiotics to Prevent Relapse After Hospitalization for Mania (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=66, Completed, Sponsor: Sheppard Pratt Health System
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date, Adherence: SPERA-S: Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=112, Completed, Sponsor: University of Cagliari
Active, not recruiting --> Completed Recruiting --> Completed | N=280 --> 112 | Trial primary completion date: Jun 2015 --> May 2016
- | Phase classification: Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=11, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed | N=280 --> 112 | Trial primary completion date: Jun 2015 --> May 2016 Phase classification: P1 --> P=N/A
- | JNJ-39393406 / J&J
Enrollment closed, Trial primary completion date: Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) - Mar 8, 2017
P2, N=62, Active, not recruiting, Sponsor: K.N. Roy Chengappa
Phase classification: P1 --> P=N/A Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Dec 2016
- | Trial completion, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=68, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Dec 2016 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Microfinance Intervention to Improve Health of Trauma Survivors in DRC (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=878, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Sep 2016
- | Trial completion, Enrollment change, Trial primary completion date: Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia (clinicaltrials.gov) - Mar 1, 2017
P=N/A, N=46, Completed, Sponsor: H
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Sep 2016 Recruiting --> Completed | N=60 --> 46 | Trial primary completion date: Sep 2015 --> Apr 2016
- | Trial primary completion date: Cognitive Remediation and Sheltered Employment in Schizophrenia (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=260, Recruiting, Sponsor: H
Recruiting --> Completed | N=60 --> 46 | Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Jan 2017 --> May 2018
- | Enrollment closed: Understanding How Cognitive Remediation Works (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=244, Active, not recruiting, Sponsor: Boston University
Trial primary completion date: Jan 2017 --> May 2018 Recruiting --> Active, not recruiting
- | metformin / Generic mfg.
Trial primary completion date: Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (clinicaltrials.gov) - Feb 23, 2017
P4, N=24, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Jun 2017
- | sertraline / Generic mfg.
Enrollment change: The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels (clinicaltrials.gov) - Feb 20, 2017
P=N/A, N=29, Completed, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Feb 2017 --> Jun 2017 N=60 --> 29
- | Biomarker, Trial completion: Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels (clinicaltrials.gov) - Feb 17, 2017
P=N/A, N=70, Completed, Sponsor: Hospital Clinic of Barcelona
N=60 --> 29 Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion, Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Feb 3, 2017
P2, N=57, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2017
- Trial completion, Trial primary completion date: Omega-3 Dietary Supplements in Schizophrenia (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=50, Completed, Sponsor: Delbert Robinson
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2015
- Enrollment closed, Trial primary completion date: Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017
- Trial primary completion date: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Jan 31, 2017
P2, N=40, Active, not recruiting, Sponsor: Indiana University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Aug 2016 --> Aug 2017
- Trial primary completion date: Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=250, Recruiting, Sponsor: Centre Hospitalier Esquirol
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Enrollment closed, Trial primary completion date: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders (clinicaltrials.gov) - Jan 30, 2017
P2, N=2, Active, not recruiting, Sponsor: Mclean Hospital
Trial primary completion date: Jul 2016 --> Jul 2017 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017
- Trial primary completion date: DCS: Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=2, Enrolling by invitation, Sponsor: Mclean Hospital
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017 Trial primary completion date: Feb 2017 --> Jul 2017
- olanzapine / Generic mfg., amisulpride / Generic mfg.
Trial primary completion date, Monotherapy: COMBINE: Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy (clinicaltrials.gov) - Jan 24, 2017
P4, N=399, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Trial primary completion date: Feb 2017 --> Jul 2017 Trial primary completion date: Aug 2016 --> Apr 2019
- ||||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (clinicaltrials.gov) - Jan 13, 2017
P3, N=500, Completed, Sponsor: Indivior Inc.
Trial primary completion date: Aug 2016 --> Apr 2019 Active, not recruiting --> Completed
- L-threonic acid magnesium salt (NRCT-101) / Neurocentria
Trial primary completion date: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia (clinicaltrials.gov) - Jan 12, 2017
P4, N=60, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Mar 2018
- | bupropion / Generic mfg.
Trial completion: Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1 (clinicaltrials.gov) - Jan 11, 2017
P2, N=59, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Trial primary completion date: Sep 2016 --> Mar 2018 Recruiting --> Completed
- | Trial completion: Cognitive Enhancement Therapy for Early-Stage Schizophrenia (clinicaltrials.gov) - Jan 10, 2017
P3, N=67, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Jan 10, 2017
P2, N=57, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Feb 2018
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Sep 2017 --> Jun 2017
- Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial primary completion date: ReLiAM: Real Life Assessment of Abilify Maintena (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=200, Terminated, Sponsor: Lundbeck Canada Inc.
Trial primary completion date: Sep 2017 --> Jun 2017 Trial primary completion date: Nov 2016 --> Feb 2017
- |||| pregabalin / Generic mfg.
Trial completion, Enrollment change: PACS: Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (clinicaltrials.gov) - Jan 9, 2017
P4, N=54, Completed, Sponsor: University of Aarhus
Trial primary completion date: Nov 2016 --> Feb 2017 Recruiting --> Completed | N=70 --> 54
- AVL-3288 / Anvyl
Enrollment change, Trial termination, Trial primary completion date: Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects (clinicaltrials.gov) - Dec 30, 2016
P1, N=12, Terminated, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=70 --> 54 N=80 --> 12 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Aug 2016; PI left institution
- | Trial completion, Trial primary completion date: Cognitive Training to Enhance VA Work Program Outcomes (clinicaltrials.gov) - Dec 21, 2016
P3, N=77, Completed, Sponsor: VA Connecticut Healthcare System
N=80 --> 12 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Aug 2016; PI left institution Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016
- | Trial completion: Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia (clinicaltrials.gov) - Dec 21, 2016
P2/3, N=150, Completed, Sponsor: VA Connecticut Healthcare System
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=3, Terminated, Sponsor: University of Aarhus
N=70 --> 3 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2016; Missing ressources. The study official has left and will not be replaced
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Dec 16, 2016
P4, N=59, Active, not recruiting, Sponsor: New York State Psychiatric Institute
The study official has left and will not be replaced Recruiting --> Active, not recruiting | N=75 --> 59
- betahistine / Generic mfg.
Trial completion, Trial primary completion date: Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain (clinicaltrials.gov) - Dec 16, 2016
P2, N=39, Completed, Sponsor: Nathan Kline Institute for Psychiatric Research
Recruiting --> Active, not recruiting | N=75 --> 59 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016
- Trial completion, Trial primary completion date: RCTEDSS: Randomized Controlled Trial (RCT) of a Motivational Decision Support System (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=184, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2016
- minocycline / Generic mfg., clozapine / Generic mfg.
Trial completion, Enrollment change: Minocycline Augmentation to Clozapine (clinicaltrials.gov) - Dec 12, 2016
P4, N=14, Completed, Sponsor: Emory University
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2016 Recruiting --> Completed | N=35 --> 14
- Trial primary completion date: Understanding How Cognitive Remediation Works (clinicaltrials.gov) - Dec 9, 2016
P=N/A, N=244, Recruiting, Sponsor: Boston University
Recruiting --> Completed | N=35 --> 14 Trial primary completion date: Nov 2018 --> Feb 2019
- Trial completion: PSYCHOCOKE: Clinical and Genetic Factors Associated With Psychotic Symptoms Among Cocaine Abusers (clinicaltrials.gov) - Dec 8, 2016
P=N/A, N=417, Completed, Sponsor: Assistance Publique - H
Trial primary completion date: Nov 2018 --> Feb 2019 Recruiting --> Completed
- valacyclovir / Generic mfg.
Trial completion: To Rescue Cognition With Valaciclovir (clinicaltrials.gov) - Dec 1, 2016
P2, N=24, Completed, Sponsor: University Medical Center Groningen
Recruiting --> Completed Recruiting --> Completed